231 related articles for article (PubMed ID: 16046516)
21. Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: a cost-effectiveness analysis.
Wong C; Luk IW; Ip M; You JH
Am J Infect Control; 2014 Apr; 42(4):412-6. PubMed ID: 24679568
[TBL] [Abstract][Full Text] [Related]
22. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
Crabtree JH; Hadnott LL; Burchette RJ; Siddiqi RA
Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
[TBL] [Abstract][Full Text] [Related]
23. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis.
Kingwatanakul P; Warady BA
Adv Perit Dial; 1997; 13():281-4. PubMed ID: 9360700
[TBL] [Abstract][Full Text] [Related]
24. [Long-term results of an eradication regime against Staphylococcus aureus in patients treated with peritoneal dialysis].
Cancho B; Garduño E; Domínguez C; Blanco J; Caravaca F
Nefrologia; 2001; 21(5):464-70. PubMed ID: 11795015
[TBL] [Abstract][Full Text] [Related]
25. Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of a Randomized Open-Label Controlled Trial.
Wong PN; Tong GM; Wong YY; Lo KY; Chan SF; Lo MW; Lo KC; Ho LY; Tse CW; Mak SK; Wong AK
Perit Dial Int; 2016; 36(3):340-6. PubMed ID: 27044796
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.
Pérez-Fontán M; Rosales M; Rodríguez-Carmona A; Moncalián J; Fernández-Rivera C; Cao M; Valdés F
Adv Perit Dial; 1992; 8():242-5. PubMed ID: 1361797
[TBL] [Abstract][Full Text] [Related]
27. Exit-Site Dressing and Infection in Peritoneal Dialysis: A Randomized Controlled Pilot Trial.
Mushahar L; Mei LW; Yusuf WS; Sivathasan S; Kamaruddin N; Idzham NJ
Perit Dial Int; 2016; 36(2):135-9. PubMed ID: 26374836
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site.
Wong SS; Chu KH; Cheuk A; Tsang WK; Fung SK; Chan HW; Tong MK
Perit Dial Int; 2003 Dec; 23 Suppl 2():S153-8. PubMed ID: 17986538
[TBL] [Abstract][Full Text] [Related]
29. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children.
Chua AN; Goldstein SL; Bell D; Brewer ED
Clin J Am Soc Nephrol; 2009 Dec; 4(12):1939-43. PubMed ID: 19820132
[TBL] [Abstract][Full Text] [Related]
30. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.
Sesso R; Parisio K; Dalboni A; Rabelo T; Barbosa D; Cendoroglo M; Pignatari A; Draibe S; Ajzen H
Clin Nephrol; 1994 Jun; 41(6):370-6. PubMed ID: 8076441
[TBL] [Abstract][Full Text] [Related]
31. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients.
Johnson DW; van Eps C; Mudge DW; Wiggins KJ; Armstrong K; Hawley CM; Campbell SB; Isbel NM; Nimmo GR; Gibbs H
J Am Soc Nephrol; 2005 May; 16(5):1456-62. PubMed ID: 15788475
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes in peritoneal dialysis: impact of continuous quality provement initiatives.
Qamar M; Sheth H; Bender FH; Piraino B
Adv Perit Dial; 2009; 25():76-9. PubMed ID: 19886322
[TBL] [Abstract][Full Text] [Related]
33. Intranasal mupirocin does not prevent exit-site infections in children receiving peritoneal dialysis.
Araki Y; Hataya H; Ikeda M; Ishikura K; Honda M
Perit Dial Int; 2003; 23(3):267-9. PubMed ID: 12938828
[TBL] [Abstract][Full Text] [Related]
34. Rates and causes of peritonitis in a National Multicenter Continuous Ambulatory Peritoneal Dialysis program in Sudan: first-year experience.
Abu-Aisha H; Elhassan EA; Khamis AH; Fedail H; Kaballo B; Abdelraheem MB; Ali T; Medani S; Tammam L; Basheir I
Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):565-70. PubMed ID: 17951944
[TBL] [Abstract][Full Text] [Related]
35. Predicting the course of peritonitis in patients receiving continuous ambulatory peritoneal dialysis.
Murata GH; Fox L; Tzamaloukas AH
Arch Intern Med; 1993 Oct; 153(20):2317-21. PubMed ID: 8215734
[TBL] [Abstract][Full Text] [Related]
36. Albumin at the start of peritoneal dialysis predicts the development of peritonitis.
Wang Q; Bernardini J; Piraino B; Fried L
Am J Kidney Dis; 2003 Mar; 41(3):664-9. PubMed ID: 12612991
[TBL] [Abstract][Full Text] [Related]
37. Peritonitis prevention in continuous ambulatory peritoneal dialysis.
Luzar MA
Nephrologie; 1992; 13(4):171-7. PubMed ID: 1407258
[TBL] [Abstract][Full Text] [Related]
38. [Prophylaxis and management of catheter-associated infections in peritoneal dialysis patients: recent studies and guidelines].
Kopriva-Altfahrt G; Moser E; Prokschi A; Kraus B; Kovarik J
Wien Klin Wochenschr; 2005; 117 Suppl 6():73-82. PubMed ID: 16437337
[TBL] [Abstract][Full Text] [Related]
39. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections.
Chu KH; Choy WY; Cheung CC; Fung KS; Tang HL; Lee W; Cheuk A; Yim KF; Chan WH; Tong KL
Perit Dial Int; 2008; 28(5):505-8. PubMed ID: 18708544
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol.
Nochaiwong S; Ruengorn C; Noppakun K; Panyathong S; Dandecha P; Sood MM; Saenjum C; Awiphan R; Sirilun S; Mongkhon P; Chongruksut W; Thavorn K;
Trials; 2019 Dec; 20(1):754. PubMed ID: 31856900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
